Coronavirus Broad Spectrum Anti Viral Targets And Treatments

Coronaviruses are zoonoses viruses that belong to the Coronaviridae family of the Nidovirales order. Coronaviruses contain 4 genera: α, β, γ and δ. Among these, Alpha and Beta coronaviruses pose a major health threat to humans and other mammals. The severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic led to 8,000 people infected with a fatality of ~10% in 2002 and 2003. Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1,700 people, with a higher death rate of up to 35% since 2012. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic ravaged the globe from the end of 2019 till now, causing catastrophic health consequences. More than 521 million cases and more than 6 million deaths have been confirmed globally. And the variants of SARS-CoV-2 were conformed to escape the vaccine-induced neutralizing antibodies and immune system, causing break-through infection, and posing long-term threats. SARS-CoV-2 is constantly evolving into new variants, creating global epidemic waves. Broad-spectrum antiviral targets or treatments are also urgently needed in the event of novel coronavirus cross-species transmission in the future. It is necessary to address new vaccine designs, pan drugs and antibodies, and universal mechanisms during viral infection.

Annual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mechanism of action of the broadly acting antiviral drug remdesivir, Improving properties of the nucleobase analogue T-706 as a potential anti-SARS-CoV-2 and anti-influenza compound, Antivirals for RNA virus infections Anno 2020-2021, Broad spectrum antiviral fleximer nucleosides, SARS-CoV-2 main protease inhibitors, The search for antivirals to treat alphavirus infections, Inhibitors of Ebola Virus targeting Innate immune evasion, Uracil derivatives as non-nucleoside inhibitors of viral infections, and more. Provides the authority and expertise of leading contributors from an international board of authors Presents the latest release in the Annual Reports in Medicinal Chemistry Updated release includes the latest information on the Coronaviruses and other novel antiviral targets

Fenner and White's Medical Virology, Fifth Edition provides an integrated view of related sciences, from cell biology, to medical epidemiology and human social behavior. The perspective represented by this book, that of medical virology as an infectious disease science, is meant to provide a starting point, an anchor, for those who must relate the subject to clinical practice, public health practice, scholarly research, and other endeavors. The book presents detailed exposition on the properties of viruses, how viruses replicate, and how viruses cause disease. These chapters are then followed by an overview of the principles of diagnosis, epidemiology, and how virus infections can be controlled. The first section concludes with a discussion on emergence and attempts to predict the next major public health challenges. These form a guide for delving into the specific diseases of interest to the reader as described in Part II. This lucid and concise, yet comprehensive, text is admirably suited to the needs of not only advanced students of science and medicine, but also postgraduate students, teachers, and research workers in all areas of virology. Features updated and expanded coverage of pathogenesis and immunity Contains the latest laboratory diagnostic methods Provides insights into clinical features of human viral disease, vaccines, chemotherapy, epidemiology, and control

Scientific literature on SARS-COV-2 viruses and its variants (especially variants of concern such as the ‘Delta variant’) and important cellular targets is crucial to help researchers, virologists and clinicians around the globe to develop a new generation of safer and more effective vaccines, and other treatments to address COVID-19 disease. The accompanying damage to the many organs and tissues of SARS-Co-2-infected people also needs to be understood and researchers are using data to devise meaningful protocols for treating these symptoms. This second volume of Coronaviruses brings together more useful information about the prevention/vaccination, and chemotherapies for the potential treatment of coronavirus infections. The volume includes eight chapters: (1) Broad spectrum antivirals to combat COVID-19 The reality and challenges, (2) COVID-19: Preventive and protective control management strategies, (3) Plant-derived extracts and bioactive compounds against coronavirus progression: preventive effects, mechanistic aspects, and structures, (4) Gastroenteritis: symptoms and epidemiology of SARS-CoV-2, (5) The chronicles of coronavirus: A Chinese king who conquered the entire world, (6) Traditional medicine as a natural remedy in ARDS & COVID-19, (7) Molecular pathogenesis of human coronaviruses of the 21st century, (8) COVID-19, mental health and neuropathophysiology of pain related to temporomandibular disorder. The volume serves as a novel compilation of key data on SARS-CoV-2 and COVID-19 and represents a resource of the utmost value for all scholars studying SARS-CoV infections. It should also be of great interest to clinicians who may be facing an overwhelming number of individuals affected with COVID-19, with over 267 million global cases documented as of the first week of December 2021).

This book is a collection of chapters dealing with examples of RNA and DNA viruses, and issues such as how these gene packages have learnt to take advantage of their hosts, molecular recognition events that hosts may use to counterattack the viruses, and how researchers have developed strategies to use viruses or their parts as tools for different purposes.

SARS is a newly identified human infection caused by a corona virus unlike any other known human or animal virus in its family. The analysis of epidemiological information obtained from the sites of the outbreaks of SARS is still underway but the overall case fatality ratio is known to approach 11% although the rate among the elderly is much higher. Currently the major challenges for the treatment of SARS are: the source of the SARS virus and mode of transmission are still not well understood; there are problems with diagnostic tools; there is no effective treatment; and there is no vaccine for SARS. The above-mentioned difficulties and challenges have motivated national authorities health workers and scientists to explore the potential of complementary treatment. The results of research on integrated treatment with TCM and Western medicine showed that it is safe and that it also has some potential clinical benefits. Therefore the experts suggested that records of such experience could serve as reference material for treatment of SARS in the future. This publication is intended to share experience in the complementary treatment of SARS patients; share the experience of clinical studies in the field of traditional medicine for treatment of SARS between the physicians and researchers; and to further encourage and promote the quality of research in the filed of traditional medicine.

Most of the antibiotics now in use have been discovered more or less by chance, and their mechanisms of action have only been elucidated after their discovery. To meet the medical need for next-generation antibiotics, a more rational approach to antibiotic development is clearly needed. Opening with a general introduction about antimicrobial drugs, their targets and the problem of antibiotic resistance, this reference systematically covers currently known antibiotic classes, their molecular mechanisms and the targets on which they act. Novel targets such as cell signaling networks, riboswitches and bacterial chaperones are covered here, alongside the latest information on the molecular mechanisms of current blockbuster antibiotics. With its broad overview of current and future antibacterial drug development, this unique reference is essential reading for anyone involved in the development and therapeutic application of novel antibiotics.

A crucial issue for antiviral therapy is the fact that all antiviral substances rapidly select for resistance; thus, monitoring and overcoming resistance has become a most important clinical paradigm of antiviral therapy. This calls for cautious use of antiviral drugs and implementation of combination therapies. In parallel, efforts in drug discovery have to be continued to develop compounds with novel mode-of-action and activity against resistant strains. This book reviews the current status of antiviral therapy, from the roads to development of new compounds to their clinical use and cost effectiveness. Individual chapters address in more detail all available drug classes and outline new approaches currently under development.